Patrick Walsh - Immunic Chief Officer
| IMUX Stock | USD 1.13 0.08 6.61% |
Insider
Patrick Walsh is Chief Officer of Immunic
| Age | 40 |
| Address | 1200 Avenue of the Americas, New York, NY, United States, 10036 |
| Phone | 332 255 9818 |
| Web | https://imux.com |
Patrick Walsh Latest Insider Activity
Tracking and analyzing the buying and selling activities of Patrick Walsh against Immunic stock is an integral part of due diligence when investing in Immunic. Patrick Walsh insider activity provides valuable insight into whether Immunic is net buyers or sellers over its current business cycle. Note, Immunic insiders must abide by specific rules, including filing SEC forms every time they buy or sell Immunic'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Patrick Walsh over three months ago Acquisition by Patrick Walsh of 15000 shares of Oil Dri subject to Rule 16b-3 | ||
Patrick Walsh over six months ago Disposition of 1434 shares by Patrick Walsh of Potbelly at 10.76 subject to Rule 16b-3 | ||
Patrick Walsh over a year ago Sale by Patrick Walsh of 10000 shares of BJs Restaurants |
Immunic Management Efficiency
The company has return on total asset (ROA) of (0.909) % which means that it has lost $0.909 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1624) %, meaning that it created substantial loss on money invested by shareholders. Immunic's management efficiency ratios could be used to measure how well Immunic manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.81 in 2024. Return On Capital Employed is likely to rise to -3.19 in 2024. At this time, Immunic's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 70.8 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 1.7 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MD | Generation Bio Co | 55 | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| MS MBA | Generation Bio Co | 46 | |
| Andrew MBA | Shattuck Labs | 38 | |
| Nik Chetwyn | Erasca Inc | N/A | |
| Behrad Derakhshan | Edgewise Therapeutics | 44 | |
| Stewart Fisher | C4 Therapeutics | 57 | |
| Lisa TesvichBonora | Erasca Inc | N/A | |
| MD MBA | Generation Bio Co | 46 | |
| Erin JD | Shattuck Labs | 44 | |
| MPH MD | Spruce Biosciences | 54 | |
| Abhinav Shukla | Shattuck Labs | ||
| MD III | Spruce Biosciences | 54 | |
| Gwenn Hansen | Nurix Therapeutics | 53 | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Silvia Buonamici | Monte Rosa Therapeutics | N/A | |
| David MD | Erasca Inc | 40 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Kelly Schick | C4 Therapeutics | 44 | |
| Marni Kottle | Kronos Bio | N/A | |
| Noreen MD | Kezar Life Sciences | 59 | |
Management Performance
| Return On Equity | -2.16 | ||||
| Return On Asset | -0.91 |
Immunic Leadership Team
Elected by the shareholders, the Immunic's board of directors comprises two types of representatives: Immunic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immunic. The board's role is to monitor Immunic's management team and ensure that shareholders' interests are well served. Immunic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immunic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| JD MBA, Executive Chairman | ||
| Patrick Walsh, Chief Officer | ||
| Glenn CPA, Chief Officer | ||
| Andreas MD, Chief Officer | ||
| Daniel Vitt, President CEO, Director | ||
| Inderpal Singh, General Counsel | ||
| Jessica Breu, Head Communications | ||
| Jason MBA, COO President | ||
| Werner Gladdines, Chief Officer | ||
| MBA MD, Ex Chairman | ||
| Hella Kohlhof, Chief Scientific Officer |
Immunic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immunic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.16 | ||||
| Return On Asset | -0.91 | ||||
| Current Valuation | 41.82 M | ||||
| Shares Outstanding | 90.08 M | ||||
| Shares Owned By Insiders | 3.43 % | ||||
| Shares Owned By Institutions | 64.84 % | ||||
| Number Of Shares Shorted | 4.19 M | ||||
| Price To Earning | (6.65) X | ||||
| Price To Book | 2.43 X | ||||
| EBITDA | (99.11 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immunic Stock Analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.